Not yet recruiting. Only at Georgia Cancer Center, at Augusta University

"Current clinical trials are showing that patients whose tumors are mismatch repair deficient (MSI) are more likely to respond to immune-boosting anti-PD-1 drugs—such as pembrolizumab—than those with tumors proficient in mismatch repair (MRP or MSS). The idea is that the greater the number of DNA glitches in a tumor cell, the more abnormal proteins it will produce—and the more abnormal proteins that are generated, the greater the odds that the body's immune cells will regard the tumor cells as "foreign" and target them for destruction. Thus far, PD-1 inhibitors have shown great promise for mismatch repair deficient cancer patients, but not for mismatch repair proficient (MRP) cancer patients.

In this clinical trial, the investigators hypothesize that treating MRP colon cancer patients with immunostimulating agent poly-ICLC will generate an inflammatory response, increasing epitope recognition and development of tumor reactive T-cells at the tumor site. However, interferon alpha and gamma produced by the poly-ICLC will increase PD-L1 expression and limit new T-cell development. Thus, PD1 blockade will increase the effectiveness of treatment with pembrolizumab."

An interesting trial, aimed exclusively to microsatellite stable CRC (the %85 of CRC). It combines TAS-102 (Lonsurf, oral, approved for mCRC) with nivolumab (Opdivo, anti PD-1 immunotherapy, approved for many other cancers; it would be an off-label use). (Not medical advice but the point is that the trial combination might be reproducible under the care of some oncologist who judges this worhty.)

The purpose of this study https://www.mskcc.org/cancer-care/clini ... als/15-048 is to assess the safety of combining two drugs, varlilumab and nivolumab, in patients with advanced solid tumors that have continued to grow despite treatment. Varlilumab is an investigational drug that binds to a protein on immune cells called CD27, which makes the immune system stronger. Nivolumab is a form of immunotherapy. It works by attaching to and blocking a molecule called PD-1, which shuts down the immune response. It is hoped that by binding to these proteins, this drug combination can activate the immune system and enhance the body’s ability to detect and destroy cancer cells.

My friend will likely be trying Tremelimumab with Durvalumab in Toronto under NCT02870920 but he has been told he has to do a targeted therapy first. Folfiri and Folfox have already failed him. I'll post any updates here that he has if and when he finally gets accepted into the trial -hopefully soon. I'm going to read up on Maia's links on the combo now.

Maia wrote:NCT02888743Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancerhttps://clinicaltrials.gov/show/NCT02888743

All 3 arms receive the 2 immuno drugs: A: two drugs without radiation; B: two drugs with radiation at a low dose; C: B: two drugs with radiation at a higher dose.Lesion to be radiated has to be in liver.Only for MSS

(Patients on the CRC arm need to have: "Microbiology Susceptibility Subcategory (MSS) tumor as documented by either: Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1, MSH-2, PMS2 or MSH6 Polymerase chain reaction (PCR) testing that does not suggest microsatellite instability (MSI))

Looking for participants with advanced lung or colorectal cancer to undergo a combined treatment with different targeted therapies More info and site information is available at this link : colorectal cancer Clinical Trial

In a nutshellThis phase 1/2 trial aims to study the safety and effectiveness of the treatment with different targeted therapy in patients with advanced lung or colorectal cancer. The main outcome to be measured is the response rate of the tumor to the treatment and the negative side effects. This trial is recruiting in California, Illinois and Texas, United States.

How will it workPatients will receive increasing doses, by injection, of azacitidine over days 1 and 7, pembrolizumab over 30 minutes every 3 weeks on day 1 and epacadostat tablets twice daily. Treatment will repeat until disease progression or unacceptable side effects. Participants will be followed for up to 18 months.